Zevtera oogun aporo (Ceftobiprole medocaril) fọwọsi nipasẹ FDA fun itọju CABP, ABSSSI ati SAB. 

cephalosporin iran karun-pupọ ogun aporo, Zevtera (Ceftobiprole medocaril soda Inj.) ti fọwọsi nipasẹ FDA¹ fun awọn itọju ti mẹta arun viz.  

1. Staphylococcus aureus awọn akoran ẹjẹ (bacteremia) (SAB), pẹlu awọn ti o ni endocarditis ti o ni apa ọtun;  

2. awọ ara kokoro-arun nla ati awọn akoran eto awọ ara (ABSSSI); ati  

3. pneumonia kokoro arun ti o gba ti agbegbe (CABP).  

Eyi tẹle awọn abajade idanwo ile-iwosan alakoso 3 itelorun.  

Ceftobiprole medocaril jẹ itẹwọgba ni ọpọlọpọ awọn orilẹ-ede Yuroopu, bakanna bi Ilu Kanada fun itọju pneumonia ti ile-iwosan ti gba (laisi pneumonia ti a gba afẹfẹ) ati pneumonia ti agbegbe ti gba ni awọn agbalagba.².  

Ni UK, Ceftobiprole medocaril wa lọwọlọwọ ni idanwo ile-iwosan alakoso III³ sibẹsibẹ, o ti gba fun ihamọ lilo laarin NHS Scotland⁴.  

Ni EU, o han ninu Iforukọsilẹ Iṣọkan ti awọn ọja oogun ti a kọ fun lilo eniyan⁵. 

Ceftobiprole medocaril, iran karun jakejado-julọ.Oniranran cephalosporin munadoko lodi si awọn kokoro arun Giramu-rere gẹgẹbi methicillin-sooro Staphylococcus aureus ati penicillin-sooro Streptococcus pneumoniae, ati lodi si Giramu-odi kokoro arun bi Pseudomonas aeruginosa. O ti rii pe o wulo ni itọju ti pneumonia ti agbegbe ti gba ati pneumonia nosocomial, ayafi fun pneumonia ti o niiṣe pẹlu atẹgun.^6,7. 

*** 

To jo:  

1. FDA Itusilẹ iroyin. FDA Fọwọsi Tuntun Kokoro Fun Awọn lilo oriṣiriṣi mẹta. Pipa 03 Kẹrin 2024. Wa ni https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses/ 

2. Jame W., Basgut B., ati Abdi A., 2024. Ceftobiprole mono-therapy dipo apapo tabi ti kii-apapọ ilana ti boṣewa egboogi fun itọju awọn akoran idiju: Atunwo eleto ati itupalẹ-meta. Aisan aisan Maikirobaoloji ati Arun Arun. Wa lori ayelujara 16 Oṣu Kẹta 2024, 116263. DOI: https://doi.org/10.1016/j.diagmicrobio.2024.116263  

3. NIHR. Finifini Imọ-ẹrọ Ilera Oṣu kọkanla 2022. Ceftobiprole medocaril fun atọju pneumonia ti ile-iwosan ti o gba tabi ẹdọfóró ti agbegbe ti o nilo ile-iwosan ni awọn ọmọde. Wa ni https://www.io.nihr.ac.uk/wp-content/uploads/2023/04/28893-Ceftobiprole-medocaril-for-pneumonia-V1.0-NOV2022-NONCONF.pdf  

4. Ijọpọ Oogun Scotland. Ceftobiprole medocaril (Zevtera). Wa ni https://www.scottishmedicines.org.uk/medicines-advice/ceftobiprole-medocaril-zevtera-resubmission-94314/  

5. Igbimọ European. Iforukọsilẹ Iṣọkan ti awọn ọja oogun ti a kọ fun lilo eniyan. Imudojuiwọn to kẹhin ni 21 Kínní 2024. Wa ni https://ec.europa.eu/health/documents/community-register/html/ho10801.htm 

6. Lupia T., et al 2022. Ceftobiprole Irisi: Lọwọlọwọ ati Awọn itọkasi ojo iwaju ti o pọju. egboogi Iwọn didun 10 Issue 2. DOI: https://doi.org/10.3390/antibiotics10020170  

7. Méndez1 R., Latorre A., ati González-Jiménez P., 2022. Ceftobiprole medocaril. Rev Esp Quimioter. 2022; 35 (Ipese 1): 25–27. Atejade lori ayelujara 2022 Oṣu Kẹrin Ọjọ 22. DOI: https://doi.org/10.37201/req/s01.05.2022  

***